Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ФГБУ «Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М.Бехтерева». 192019, Санкт-Петербург, Россия, ул. Бехтерева, д. 3; 2ФГБОУ ВО «Санкт-Петербургский государственный университет». 199034, Россия, Санкт-Петербург, Университетская наб., д. 7–9
Работа поддержана грантом РНФ 14-50-00069.
Список исп. литературыСкрыть список 1. Stober G, Ben-Shachar D, Cardon M et al. Schizophrenia: From the brain to peripheral markers – A consensus paper of the WFSBP Task Force on biological markers. World J Biol Psychiatry 2009; 10 (2): 127–55. 2. Weickert CS, Weickert TW, Pillai A, Buckley PF. Biomarkers in schizophrenia: a brief conceptual consideration. Dis Mark 2013; 35: 3–9. 3. Lakhan SE, Kramer A. Schizophrenia genomics and proteomics: are we any closer to biomarker discovery? Behav Brain Funct 2009; 5: 2. 4. Emsley R, Rabinowitz J, Medori R. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr Res 2007; 89: 129–39. 5. Notaras M, Hill R, van den Buuse M. A role for the BDNF gene Val66Met polymorphism in schizophrenia? A comprehensive review. Neurosci Biobehav Rev 2015; 51: 15–30. 6. Mehta UM, Keshavan MS. Can we predict outcome in schizophrenia? The need for prognostic biomarkers. Asian J Psychiatr 2015; 14: 1–2. 7. Schwarz E, Bahn S. Cerebrospinal fluid identification of diagnostic markers for schizophrenia. Expert Rev Mol Diagn 2008; 8 (2): 209–16. 8. English BA, Thomas K, Johnstone J et al. Use of translational pharmacodynamic biomarkers in early-phase clinical studies for schizophrenia. Biomark Med 2014; 8 (1): 29–9. 9. Бубнова Ю.С., Дорофейков В.В., Мазо Г.Э., Петрова Н.Н. К вопросу о механизмах развития депрессии при шизофрении. Психиатрия и психофармакотерапия. 2012; 14 (4): 21–6. / Bubnova Yu.S., Dorofeikov V.V., Mazo G.E., Petrova N.N. K voprosu o mekhanizmakh razvitiia depressii pri shizofrenii. Psychiatry and Psychopharmacotherapy. 2012; 14 (4): 21–6. [in Russian] 10. Noto CS, Gadelha A, Belangero SI et al. Association of biomarkers and depressive symptoms in schizophrenia. Neurosci Lett 2011; 505 (3): 282–85. 11. Maes M, Bocchio Chiavetto L, Bignotti Sn et al. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr Res 2002; 54 (3): 281–91. 12. Sugino H, Futamura T, Mitsumoto Y et al. Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33 (2): 303–7. 13. Altamura AC, Boin F, Maes M. HPA axis and cytokines dysregulation in schizophrenia: potential implications for the antipsychotic treatment. Eur Neuropsychopharmacol 1999; 10 (1): 1–4. 14. Zai G, Muller DJ, Volavka J et al. Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication. Psychopharmacology (Berl) 2006; 188 (2): 171–82. 15. Zhang XY, Zhou DF, Cao LY et al. Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology 2005; 30: 1532–8. 16. McAllister CG, van Kammen DP, Rehn TJ et al. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry. 1995; 152: 1291–7. 17. Lin A, Kenis G, Bignotti S et al. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res 1998; 32: 9–15. 18. Tomasik J, Schwarz E, Guest PC, Bahn S. Blood test for schizophrenia. Eur Arch Psychiatry Clin Neurosci 2012; 262 (Suppl. 2): 79–83. 19. Chan MK, Guest PC, Levin Y et al. Converging evidence of blood-based biomarkers for schizophrenia: an update. Int Rev Neurobiol 2011; 101: 95–144. 20. Thompson Ray M, Weickert CS, Wyatt E et al. Decreased BDNF, trkB-TK1 and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J Psychiatry Neurosci 2011; 36 (3): 195–203. 21. Jindal RD, Pillai AK, Mahadik SP et al. Decreased BDNF in patients with antipsychotic naı¨ve first episode schizophrenia. Schizophr Res 2010; 119 (1–3): 47–51. 22. Pillai A, Buckley PF. Reliable biomarkers and predictors of schizophrenia and its treatment. Psychiatr Clin North Am 2012; 35: 645–59. 23. Vinogradov S, Fisher M, Holland C et al. Is Serum Brain-Derived Neurotrophic Factor a Biomarker for Cognitive Enhancement in Schizophrenia? Biol Psychiatry 2009; 66 (6): 549-53. 24. Gama CS, Andreazza AC, Kunz M et al. Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci Lett 2007; 420: 45–8. 25. Pedrini M, Chendo I, Grande I, Lobato MI et al. Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: a positive correlation. Neurosci Lett 2011; 491: 207–10. 26. Wan S, Yang Y, Li H et al. Dysregulation of retinoid transporters expression in body fluids of schizophrenia patients. J Proteome Res 2006; 5 (11): 3213–6. 27. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13 (2): 261–76. 28. Miller BJ, Culpepper N, Rapaport MH. C-reactive protein levels in schizophrenia: a review and meta-analysis. Clin Schizophr Relat Psychoses 2014; 7: 223–30. 29. Dickerson F, Stallings C, Origoni A et al. Inflammatory Markers in Recent Onset Psychosis and Chronic Schizophrenia. Schizophr Bull 2016; 42 (1): 134–41. 30. Chao HM, Kao H-T, Porton B. BDNF Val66Met variant and age of onset in schizophrenia. American journal of medical genetics Part B, Neuropsychiatric genetics: the official publication of the International Society of Psychiatric Genetics. 2008; 147B (4): 505–6.